Logo

Precision Signs Multiple Agreements with Novartis to Develop an In Vivo Gene Editing Therapies for Sickle Cell Disease and Beta Thalassemia

Share this
Precision Signs Multiple Agreements with Novartis to Develop an In Vivo Gene Editing Therapies for Sickle Cell Disease and Beta Thalassemia

Precision Signs Multiple Agreements with Novartis to Develop an In Vivo Gene Editing Therapies for Sickle Cell Disease and Beta Thalassemia

Shots:

  • Precision to receive a $75M up front, ~$1.4B in additional milestones & is also eligible to receive research funding along with royalties on sales of licensed products & will be responsible for R&D, manufacturing & commercialization activities
  • Precision to develop a single ARCUS nuclease designed for safe & efficient in vivo gene insertion as a one-time transformative treatment option for hemoglobinopathies. Novartis to get an exclusive license to ARCUS nuclease to create in vivo treatment options for the same indication
  • The collaboration combines Precision’s ARCUS genome editing platform & gene insertion capabilities with Novartis’ drug discovery & gene therapy expertise for curative treatment in an inherited blood disorder

Ref: Bussinesswire | Image: Novartis

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions